Advice4u.com

Orexigen Partners With Takeda To Commercialize Obesity Drug Contrave (Naltrexone SR/Bupropion SR)

September 3, 2010 – 5:22 am

Contrave (naltrexone SR/bupropion SR), an investigational drug aimed at combination therapy to address both biological and behavioral drivers of obesity, will be developed and commercialized by Orexigen Therapeutics, Inc. and Takeda Pharmaceutical Company Limited in the USA, Canada and Mexico. The two drug firms have just signed an exclusive partnership for the North American area. The Contrave combination treatment targets the central pathways involved in controlling the balance of both food consumption and metabolism, as well as regulating eating behavior, Orexigen informs…

Find more info about Orexigen Partners With Takeda To Commercialize Obesity Drug Contrave (Naltrexone SR/Bupropion SR) photos videos pictures. read more

Related Info :

Tags: Address, Bupropion Sr, Central Pathways, Combination Therapy, Combination Treatment, Commercialize, Contrave, Drug, Drug Photos, Food Consumption, Investigational Drug, limited, Metabolism, Mexico, Naltrexone, Obesity, Obesity Drug, Orexigen, Orexigen Therapeutics Inc, Partners, Partnership, Pharmaceutical Company, Photos Pictures, SR/Bupropion, Takeda, Usa Canada